Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical is a company with a strong position in the cosmetic surgery market, driven by the success of its Renuvion platform. This platform utilizes a unique helium plasma technology to tighten loose or lax skin. The recently launched Ayon all-in-one body contouring system has the potential to drive further growth by providing a comprehensive solution for surgeons. Apyx's focus on the surgical skin tightening market, favorable market trends, and expanding recurring revenue mix position the company for sustainable cash flow generation and potential valuation multiple expansion.

Bears say

Apyx Medical is expected to experience a decline in revenue due to decreased demand for its Renuvion technology following the FDA's safety communication in 2022, but this could potentially be offset by the launch of its new Ayon product and expanded FDA clearance for its J-Plasma system in 2026. However, risks such as potential liability from product liability matters, inconsistent commercial execution, and regulatory delays could impact the company's financial performance. Additionally, with a history of net losses and significant outstanding debt, the company's financial stability could be a concern.

APYX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 5 analysts, APYX has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.